AnaptysBio (ANAB) Stock Price, News & Analysis

Company Overview

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Key Stats

• Today's Range: $20.17 to $21.14
• 50-Day Range: $14.64 to $21.58
• 52-Week Range: $12.21 to $41.31
• Volume: 306,123 shs
• Average Volume: 597,603 shs
• Market Capitalization: $634.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.63
• Consensus Rating: Moderate Buy

AnaptysBio Stock Analysis - MarketRank™

AnaptysBio scored higher than 48% of companies evaluated by MarketBeat, and ranked 546th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

AnaptysBio has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AnaptysBio are expected to grow in the coming year, from ($6.08) to ($5.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AnaptysBio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AnaptysBio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AnaptysBio has a P/B Ratio of 6.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

53.39% of the float of AnaptysBio has been sold short.

Short Interest Ratio / Days to Cover

AnaptysBio has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.

Change versus previous month

Short interest in AnaptysBio has recently increased by 0.37%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AnaptysBio does not currently pay a dividend.

Dividend Growth

AnaptysBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

53.39% of the float of AnaptysBio has been sold short.

Short Interest Ratio / Days to Cover

AnaptysBio has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.

Change versus previous month

Short interest in AnaptysBio has recently increased by 0.37%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.39

News Sentiment

AnaptysBio has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for AnaptysBio this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for ANAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AnaptysBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.70% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

ANAB Stock Analysis - Frequently Asked Questions

How have ANAB shares performed this year?

AnaptysBio's stock was trading at $13.24 at the start of the year. Since then, ANAB shares have increased by 56.3% and is now trading at $20.70.
View the best growth stocks for 2025 here.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) posted its earnings results on Thursday, February, 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. The biotechnology company had revenue of $43.11 million for the quarter, compared to analysts' expectations of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative trailing twelve-month return on equity of 287.94%.

Is AnaptysBio buying back stock?

AnaptysBio's board authorized a stock buyback plan on Monday, March 24th 2025, which authorizes the company to buy back $75,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 13.1% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board believes its shares are undervalued.

When did AnaptysBio IPO?

AnaptysBio (ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are AnaptysBio's major shareholders?

Top institutional shareholders of AnaptysBio include Assenagon Asset Management S.A. (0.79%), HighMark Wealth Management LLC (0.30%), Rhumbline Advisers (0.10%) and GAMMA Investing LLC (0.02%). Insiders that own company stock include Ecor1 Capital, Llc, Paul F Lizzul, Eric J Loumeau, Dennis Mulroy, Hollings Renton and Dennis M Fenton.
View institutional ownership trends.

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 4/27/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANAB
• CIK: 1370053
• Web: www.anaptysbio.com
• Phone: (858) 362-6295
• Fax: N/A
• Employees: 100
• Year Founded: 2005

Price Target and Rating

• Average Stock Price Target: $33.63
• High Stock Price Target: $51.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +62.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-163,620,000.00
• Net Margins: -289.75%
• Pretax Margin: -289.74%
• Return on Equity: -287.94%
• Return on Assets: -37.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.23
• Quick Ratio: 10.23

Sales & Book Value

• Annual Sales: $91.28 million
• Price / Sales: 6.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.32 per share
• Price / Book: 6.23

Miscellaneous

• Outstanding Shares: 30,667,000
• Free Float: 20,174,000
• Market Cap: $634.81 million
• Optionable: Optionable
• Beta: -0.09